BRPI0909818A2 - métodos, formas de dosagem e conjunto para administrar ziprasidona sem alimentos - Google Patents

métodos, formas de dosagem e conjunto para administrar ziprasidona sem alimentos

Info

Publication number
BRPI0909818A2
BRPI0909818A2 BRPI0909818A BRPI0909818A BRPI0909818A2 BR PI0909818 A2 BRPI0909818 A2 BR PI0909818A2 BR PI0909818 A BRPI0909818 A BR PI0909818A BR PI0909818 A BRPI0909818 A BR PI0909818A BR PI0909818 A2 BRPI0909818 A2 BR PI0909818A2
Authority
BR
Brazil
Prior art keywords
kit
food
methods
dosage forms
ziprasidone
Prior art date
Application number
BRPI0909818A
Other languages
English (en)
Portuguese (pt)
Inventor
Avinash Govind Thombre
Christopher Donavan Craig
David Keith Lyon
Dwayne Thomas Friesen
Jaymin Chandrakant Shah
Scott Max Herbig
Sheri L Shamblin
Timothy LUKAS
William Brett Caldwell
William John Curatolo
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BRPI0909818A2 publication Critical patent/BRPI0909818A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0909818A 2008-03-07 2009-03-04 métodos, formas de dosagem e conjunto para administrar ziprasidona sem alimentos BRPI0909818A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3494708P 2008-03-07 2008-03-07
PCT/IB2009/000442 WO2009109844A1 (en) 2008-03-07 2009-03-04 Methods, dosage forms, and kits for administering ziprasidone without food

Publications (1)

Publication Number Publication Date
BRPI0909818A2 true BRPI0909818A2 (pt) 2015-10-06

Family

ID=40720011

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0909818A BRPI0909818A2 (pt) 2008-03-07 2009-03-04 métodos, formas de dosagem e conjunto para administrar ziprasidona sem alimentos

Country Status (15)

Country Link
US (1) US20110002989A1 (OSRAM)
EP (1) EP2280711A1 (OSRAM)
JP (1) JP2009215293A (OSRAM)
KR (1) KR20100131477A (OSRAM)
CN (1) CN102014910A (OSRAM)
AR (1) AR070964A1 (OSRAM)
AU (1) AU2009220925A1 (OSRAM)
BR (1) BRPI0909818A2 (OSRAM)
CA (1) CA2719115A1 (OSRAM)
IL (1) IL207792A0 (OSRAM)
MX (1) MX2010009844A (OSRAM)
RU (1) RU2010135831A (OSRAM)
TW (1) TW200950783A (OSRAM)
WO (1) WO2009109844A1 (OSRAM)
ZA (1) ZA201005905B (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010082855A1 (en) * 2009-01-15 2010-07-22 Zaklady Farmaceutyczne Polpharma Sa Pharmaceutical compositions comprising ziprasidone free base or ziprasidone hydrochloride and the method for their preparation
US9510148B2 (en) * 2009-03-03 2016-11-29 Mobilitie, Llc System and method for wireless communication to permit audience participation
KR102337598B1 (ko) * 2013-05-03 2021-12-10 신닥스 파마슈티컬스, 인크. 암 치료 방법
MX2016001304A (es) 2013-07-30 2016-04-07 Gilead Connecticut Inc Polimorfo de inhibidores de syk.
PT3027171T (pt) 2013-07-30 2020-06-18 Gilead Connecticut Inc Formulação de inibidores da syk
WO2015082562A1 (en) * 2013-12-05 2015-06-11 Alrise Biosystems Gmbh Process for the production of drug formulations for oral administration
TWI735853B (zh) 2013-12-23 2021-08-11 美商克洛諾斯生技有限公司 脾酪胺酸激酶抑制劑
US10474345B2 (en) * 2014-04-04 2019-11-12 Shawn SHEY User interfaces and methods for displaying content
AU2015317468B2 (en) * 2014-09-19 2018-06-14 The Procter & Gamble Company Process for making a core with an active coating
WO2016198983A1 (en) 2015-06-09 2016-12-15 Bend Research Inc. Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
CA2987081C (en) 2015-06-11 2022-08-30 Alrise Biosystems Gmbh Process for the preparation of drug loaded microparticles
CN107714669A (zh) * 2016-08-11 2018-02-23 广东东阳光药业有限公司 齐拉西酮缓释剂及其制备方法
CN115028640A (zh) 2017-08-25 2022-09-09 吉利德科学公司 Syk抑制剂的多晶型物
KR20210131372A (ko) 2019-02-22 2021-11-02 크로노스 바이오, 인코포레이티드 Syk 억제제로서의 축합된 피라진의 고체 형태

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003000226A2 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
BRPI0414082A (pt) * 2003-09-02 2006-10-24 Pfizer Prod Inc formas de dosagem de liberação sustentada de ziprasidona
US7825106B2 (en) * 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease
WO2005065660A2 (en) * 2003-12-31 2005-07-21 Alpharma, Inc. Ziprasidone formulations
WO2005123086A2 (en) * 2004-06-11 2005-12-29 Dr. Reddy's Laboratories Ltd. Ziprasidone dosage form
EP1901722A4 (en) * 2005-06-20 2011-06-15 Elan Pharma Int Ltd NANOTEHOUS COMPOSITIONS WITH CONTROLLED RELEASE FROM ARYL-HETEROCYCLIC COMPOUNDS

Also Published As

Publication number Publication date
RU2010135831A (ru) 2012-04-20
AR070964A1 (es) 2010-05-19
MX2010009844A (es) 2010-09-30
EP2280711A1 (en) 2011-02-09
WO2009109844A1 (en) 2009-09-11
JP2009215293A (ja) 2009-09-24
CA2719115A1 (en) 2009-09-11
AU2009220925A1 (en) 2009-09-11
TW200950783A (en) 2009-12-16
CN102014910A (zh) 2011-04-13
US20110002989A1 (en) 2011-01-06
IL207792A0 (en) 2010-12-30
KR20100131477A (ko) 2010-12-15
ZA201005905B (en) 2011-11-30

Similar Documents

Publication Publication Date Title
BRPI0909818A2 (pt) métodos, formas de dosagem e conjunto para administrar ziprasidona sem alimentos
LTPA2020006I1 (lt) GDF gaudyklės, skirtos naudoti anemijos gydymui
BRPI0922233A2 (pt) compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas.
ATE488227T1 (de) Feste zubereitung mit alogliptin und pioglitazon
BRPI0813725A2 (pt) Métodos e composições para tratamento de doenças
BRPI0918652A2 (pt) Composições farmacêuticas e métodos de libração relacionadas.
BRPI0922122A2 (pt) composições e métodos para tratamento de doença celíaca.
BRPI0906962A2 (pt) Composto, e, composição farmacêutica
BRPI0906556A2 (pt) Composto, e, composição farmacêutica
BRPI1009824A2 (pt) dispersão sólida e forma farmacêutica sólida.
BR112012022879A2 (pt) composto, composição farmacêutica, uso do composto e método de tratamento
BRPI0909770A2 (pt) Vacina, e, kit
BRPI1016199A2 (pt) cobertura de ferimento e kit de tratamento de ferimentos.
BRPI0905369A2 (pt) Composição farmacêutica, composição e kit compartimentado
BRPI0810525A2 (pt) Composições e métodos para a profilaxia e tratamento de dependência química
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
PL2354161T3 (pl) Przeciwciało anty -NR10 i jego zastosowanie
EP2307344A4 (en) OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, PREPARATION AND USE THEREOF
BRPI0917681A2 (pt) Composto, e, composição farmacêutica
BRPI0919794A2 (pt) dispositivo para uso intracorpóreo, e, composto
BRPI0906606A2 (pt) Tratamento terapêutico para condições do pulmão.
BRPI0913175A2 (pt) artigo antibalístico, e, uso do mesmo.
BRPI0912687A2 (pt) uso de bactéria probiótica para o tratamento de hiperhomocisteinaemia
EP2106253A4 (en) TREATMENT OF ACOUPHEN
BRPI0821901A2 (pt) Válvula homogeneizadora

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.